Recommended Articles
Startups

Abbott to Spin Off Nutrition Business Into Public Company

By Angeled · October 22, 2026 · Startups
Abbott to Spin Off Nutrition Business Into Public Company
Abbott to Spin Off Nutrition Business Into Public Company

The news

On October 21, 2026, Abbott Laboratories (NYSE: ABT) announced plans to separate its nutrition business — home to the Similac infant formula and Ensure nutritional drink brands — into a standalone publicly traded company. The unit generated more than $8 billion in sales last year. Abbott expects the separation to be complete in 2027.

The announcement came alongside a cut to Abbott's 2026 sales growth forecast. CEO Robert Ford struck an upbeat tone on the post-earnings call, telling analysts that outstanding legal disputes were unlikely to delay the separation and describing a decade of "differentiated and kind of high growth" segments ahead for the nutrition business. Abbott shares fell about 4% in morning trading.

The separation

The spinoff sheds a beleaguered unit that has dragged on the parent for years. Abbott's baby formula business has faced a chain of setbacks since the 2022 recall and shutdown of its Sturgis, Michigan plant, which triggered a nationwide infant formula shortage. The division lost a major US government supply contract last year, faced higher manufacturing costs that forced price increases and hurt demand, and continues to face lawsuits alleging its specialized formula for premature infants caused a potentially fatal bowel disease.

Patrick Wood, head of U.S. MedTech Research at UBS, said the logic is sound: "Running a consumer goods business is very different from running a medical devices business." As a standalone, the nutrition company will deal with retailers, consumer trends, and formula manufacturing directly; Abbott will focus on medical devices, diagnostics, and pharmaceuticals. But separation raises a live question — flagged by Brookings senior fellow Marta Wosińska — about where litigation liability lands in the new structure.

Background and context

Abbott is the latest giant to conclude that conglomerates are worth less than the sum of their parts. Johnson & Johnson spun off its consumer-health business as Kenvue in 2023; GE completed its three-way breakup into GE HealthCare, GE Vernova, and GE Aerospace; Medtronic has announced separations of its own. The pattern is consistent: focus the parent on higher-growth, higher-margin segments (devices, diagnostics, pharma) and let the slower consumer business live or die on its own capital allocation.

Spinoffs typically unlock value two ways. First, the "conglomerate discount" — investors apply a lower multiple to a company with mixed growth profiles — disappears when each business gets priced on its own merits. Second, capital allocation improves: management of a pure-play consumer company invests differently than a CEO splitting attention across Formula One-level medtech R&D and grocery-aisle formula pricing.

The infant formula category adds a specific wrinkle. It is an emotive, heavily regulated, concentrated market where quality failures trigger national crises — the 2022 Sturgis shutdown became a White House-level problem. A standalone nutrition company will be judged almost entirely on its ability to manufacture reliably and navigate WIC government contracts, litigation, and retail relationships. That clarity is exactly what Abbott is buying — for both entities.

Why it matters for founders

Corporate separations create startups' favorite kind of opening: newly independent companies with fresh mandates, fresh budgets, and urgent vendor needs. A standalone nutrition business with $8B+ in revenue will be rebuilding its technology stack, supply-chain systems, and compliance infrastructure — all of which are founder-sized opportunities. Watch the spinoff's executive appointments and early RFPs the way you'd watch a fresh funding round.

The deeper lesson is about focus as a competitive weapon. Abbott's thesis — "running a consumer goods business is very different from running a medical devices business" — is the same argument that kills startups: trying to serve two fundamentally different operating models under one roof. If your company spans two businesses with different customers, different sales cycles, and different regulatory regimes, Abbott just demonstrated the board-level answer.

Why it matters for investors

Spinoff investing has a long empirical record: studies from the Journal of Finance and others have found parent and spun-off entities tend to outperform the broad market in the years after separation. The mechanism is real — focused management teams, cleaner incentive structures, and the end of internal cross-subsidization.

For private investors, the watch list is the corporate-separation pipeline. Every Fortune 500 breakup creates a newly listed company with a clean balance sheet, a growth mandate, and an appetite for M&A of its own — and often a parent company with freshly freed capital to redeploy into higher-margin segments. Abbott's device, diagnostics, and pharma businesses just got permission to spend like pure plays. If you invest in medtech or diagnostics, your acquirer map got simpler and sharper today.

Angeled.com connects founders with investors.

Read Next